Beximco Pharmaceuticals (R2WA) Stock Overview
Manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
R2WA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Beximco Pharmaceuticals PLC. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳0.51 |
| 52 Week High | ৳0.79 |
| 52 Week Low | ৳0.37 |
| Beta | 0.062 |
| 1 Month Change | -1.92% |
| 3 Month Change | 13.33% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -47.96% |
| Change since IPO | 2.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| R2WA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 7.1% | -0.9% | 0.3% |
| 1Y | n/a | 24.7% | 5.6% |
Return vs Industry: Insufficient data to determine how R2WA performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how R2WA performed against the German Market.
Price Volatility
| R2WA volatility | |
|---|---|
| R2WA Average Weekly Movement | 23.6% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 13.4% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: R2WA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: R2WA's weekly volatility has increased from 16% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 1,122 | Iqbal Ahmed | www.beximcopharma.com |
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies.
Beximco Pharmaceuticals PLC. Fundamentals Summary
| R2WA fundamental statistics | |
|---|---|
| Market cap | €373.79m |
| Earnings (TTM) | €43.78m |
| Revenue (TTM) | €319.32m |
Is R2WA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R2WA income statement (TTM) | |
|---|---|
| Revenue | ৳46.34b |
| Cost of Revenue | ৳25.76b |
| Gross Profit | ৳20.58b |
| Other Expenses | ৳14.23b |
| Earnings | ৳6.35b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.24 |
| Gross Margin | 44.42% |
| Net Profit Margin | 13.71% |
| Debt/Equity Ratio | 10.8% |
How did R2WA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/15 23:56 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beximco Pharmaceuticals PLC. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| S M Toufique Imran | BRAC EPL Stock Brokerage Ltd |
| Asif Khan | EDGE Research & Consulting |
| Lorenza Castellon | Equity Development Limited |